Short-term adverse effects of anticancer drugs in patients with type 2 diabetes.
Agostino MilluzzoAndrea TumminiaVeronica VellaFiorenza GianìLivia ManzellaLucia FrittittaErnestina Marianna De FrancescoRiccardo VigneriLaura SciaccaPublished in: Journal of chemotherapy (Florence, Italy) (2019)
The short-term adverse effects of anticancer drugs (AD) in patients with type 2 diabetes (T2D) are poorly studied and their management still represents an important challenge for clinicians. We carried out a retrospective single-center study in 168 patients with T2D and cancer, evaluating both the short-term effects of first-line AD on glycemic control and chronic diabetes complications. Average glycated hemoglobin significantly increased after AD compared to values before treatment (7.5 vs. 7.1%, p < 0.005). In 46.4% of patients, diabetes therapy had to be potentiated, in most cases (82.1%) by shifting to insulin. The use of alkylating agents and high-dose glucocorticoids predicted the need to potentiate diabetes therapy. After AD transaminase values significantly increased, whereas the estimated glomerular filtration rate decreased (in 12.5% <60 mL/min). Kinase inhibitors significantly increased the risk of microalbuminuria onset or progression. The present study provides a real-life information on the effects of different AD on the management of patients with T2D affected by several types of cancer.
Keyphrases
- glycemic control
- type diabetes
- blood glucose
- papillary thyroid
- high dose
- weight loss
- end stage renal disease
- insulin resistance
- squamous cell
- cardiovascular disease
- newly diagnosed
- chronic kidney disease
- ejection fraction
- low dose
- palliative care
- risk factors
- prognostic factors
- stem cells
- lymph node metastasis
- squamous cell carcinoma
- healthcare
- health information
- metabolic syndrome
- cell therapy
- peritoneal dialysis
- skeletal muscle
- smoking cessation